Financials data is unavailable for this security.
View more
Year on year Xenetic Biosciences Inc grew revenues 48.80% from 1.71m to 2.54m while net income improved from a loss of 6.55m to a smaller loss of 4.13m.
| Gross margin | -- |
|---|---|
| Net profit margin | -186.33% |
| Operating margin | -198.71% |
| Return on assets | -43.12% |
|---|---|
| Return on equity | -48.62% |
| Return on investment | -48.61% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Xenetic Biosciences Inc fell by 4.11m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 4.11m for operations while cash used for financing totalled .
| Cash flow per share | -3.05 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.83 |
|---|---|
| Tangible book value per share | 4.83 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.05 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
